期刊文献+

M型磷脂酶A2受体抗体阳性与阴性的原发性膜性肾病患者的临床与病理特点比较 被引量:1

The differences in clinical and pathological features between patients positive and negative for M-type phospholipase A2 receptor antibody in idiopathic membranous nephropathy
下载PDF
导出
摘要 目的比较M型磷脂酶A2受体抗体阳性与阴性的原发性膜性肾病患者的临床与病理特点。方法选取2015年5月至2017年10月北京大学第三医院肾内科147例原发性膜性肾病患者,根据血清抗PLA2R抗体检测结果分为PLA2R抗体阳性组和抗体阴性组。回顾分析临床及病理资料。结果抗体阳性组尿蛋白检测为(7.55±6.10)g/24h,抗体阴性组为(5.10±4.10)g/24h,抗体阳性组血清清蛋白为(27.71±5.93)g/L,抗体阴性组为(33.07±7.03)g/L,两组比较差异有统计学意义(P<0.05)。抗体阳性组估算的肾小球滤过率为(107.35±33.47)mL·min-1·1.73 m-2,抗体阴性组为(107.21±36.64)mL·min-1·1.73m-2,两组差异无统计学意义(P>0.05);在临床诊断方面,抗体阳性组肾病综合征的比例为80.00%,抗体阴性组肾病综合征比例为54.39%,两组差异有统计学意义(P<0.05);在肾脏病理方面,肾脏组织中IgG、IgM、IgA、IgG 1~4及C1q的沉积在抗体阳性组和抗体阴性组间差异无统计学意义(P>0.05),但两组C3沉积的差异有统计学意义(P<0.05);在治疗上,抗体阳性组中使用免疫抑制治疗的比例为82.22%,抗体阴性组的比例为57.89%,两组差异有统计学意义(P<0.05);在转归方面,抗体阳性组缓解率(包括完全缓解和部分缓解)为60.00%,抗体阴性组的缓解率为63.20%,差异无统计学意义(P>0.05)。结论在原发性膜性肾病中,相较于M型磷脂酶A2受体抗体阴性者,抗体阳性者临床上肾病综合征的表现更突出,肾组织中C3沉积较多,需要使用免疫抑制治疗的可能性更大。 Objective To compare the clinical and pathological features of patients who were positive and negative for M-type phospholipase A2 receptor(PLA2 R)antibody in idiopathic membranous nephropathy.Methods The clinical and pathological data of 147 cases of membranous nephropathy who were performed with renal biopsy in Peking University Third Hospital from May 2015 to October 2017 were retrospectively analyzed.Results There were no statistical significance in age and sex between the antibody-positive group and the antibody-negative group.The proteinuria levels were(7.55±6.10)g/24 hand(5.10±4.10)g/24 h respectively in PLA2 R positive and negative group.Serum albumin levels were(27.71±5.93)g/L and(33.07±7.03)g/L respectively.There was a statistically significant difference between the two groups(P〈0.05).The estimated GFR were(107.35±33.47)mL·min-1·1.73 m-2 and(107.21±36.64)mL·min-1·1.73 m-2 respectively.There was no significant difference between the two groups.In terms of clinical diagnosis,the ratio of nephrotic syndrome in PLA2 Rantibody positive group and negative group was 80.00% and54.39%respectively.The difference between the two groups was statistically significant(P〈0.05).In the kidney pathology,IgG,IgM,IgA,IgG 1-4 and C1 q deposition in kidney tissue were similar in both groups.But the difference of C3 deposition between the two groups were statistically significant(P〈0.05).The usage rate of immunosuppressive therapy in the PLA2 Rantibody positive group and antibody-negative group were82.22% and 57.89%respectively.There was a statistical difference between the two groups(P〈0.05).The remission rates(including complete remission and partial remission)were similar in both groups,which was60.00% and 63.20%respectively.Conclusion Compared with PLA2 Rantibody-negative patients,the PLA2 R antibody-positive idiopathic membranous nephropathy patients usually have more severe clinical manifestations.There is a high incidence of C3 deposition in the kidney tissue.And the need to use immunosuppressive therapy is more greater.
作者 林矗 刘晶 郑丹侠 王悦 王松 LIN Chu;LIU Jing;ZHENG Danxia;WANG Yue;WANG Song(Peking University Health Science Center,Beijing 100191,China;Department of Clinical Laboratory,Peking University Third Hospital,Beijing 100191,China;Department of Nephrology,Peking University Third Hospital,Beijing 100191,China)
出处 《国际检验医学杂志》 CAS 2018年第14期1679-1682,共4页 International Journal of Laboratory Medicine
关键词 原发性膜性肾病 M型磷脂酶A2受体抗体 肾病综合征 idiopathic membranous nephropathy M type phospholipase A2 receptor antibody
  • 相关文献

参考文献5

二级参考文献89

  • 1Xing GQ, Chert M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol, 2009, 29: 282-291.
  • 2Adler S, Salant DJ, Dittmer JE, et al. Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen. Kidney Int, 1983, 23: 807-815.
  • 3Debiec H, Gnigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti - neutral endopeptidase antibodies. N Engl J Med, 2002, 346: 2053- 2060.
  • 4Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009, 361: 11-21.
  • 5Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soe Nephrol, 2010, 21: 507-519.
  • 6Kriz W, Hackenthal E, Nobiling R, et al. A role for podocytes to counteract capillary wall distension. Kidney Int, 1994, 45: 369-376.
  • 7Yu D, Petermann A, Kunter U, et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol, 2005, 16: 1733-1741.
  • 8Hara M, Yanagihara T, Kihara I, et al. Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol, 2005, 16: 408-416.
  • 9Salant DJ, Belok S, Madaio MP, et al. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest, 1980, 66: 1339-1350.
  • 10Baker PJ, Ochi RF, Schulze M, et al. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol, 1989, 135: 185-194.

共引文献55

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部